Focus on Anticoagulation Care

Back to articles

Extended anticoagulation with rivaroxaban beneficial for preventing recurrent VTEs

KEY POINT

In a benefit–risk analysis from the EINSTEIN-Extension study, continued use of rivaroxaban (Xarelto—Janssen) in patients with symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) who had already completed 6 to 12 months of anticoagulation was shown to result in fewer recurrent venous thromboembolisms (VTEs) compared with placebo, and patients had a low frequency of major bleeding events.